JAMA Network
About The Study: In this nationally representative analysis, applying low-density lipoprotein cholesterol (LDL-C) goals from the 2026 American College of Cardiology/American Heart Association dyslipidemia guideline to 2021 to 2023 U.S. population data revealed substantial gaps in LDL-C control, with an increasing gradient across primary prevention categories and high proportions among adults with established atherosclerotic cardiovascular disease. These gaps were accompanied by substantial underuse of lipid-lowering therapy. These findings provide a contemporary population-level benchmark for the updated guideline framework.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
